BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

S*Bio of Singapore Sells Cancer Drug Rights to MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) for $75 Million


8/10/2012 2:24:37 PM

by Richard Daverman, PhD

August 10, 2012 -- S*BIO of Singapore has sold worldwide rights for a clinical stage oncology drug to MEI Pharma of San Diego. Pracinostat is an oral histone deacetylase (HDAC) inhibitor. The drug has completed Phase II clinical trials in patients with hematologic disorders such as acute myeloid leukemia and myelofibrosis. To make the acquisition, MEI Pharma will issue $500,000 of common stock to S*BIO, and it agreed to pay S*BIO up to $75.2 million if clinical, regulatory and sales milestones are met. The agreement also calls for low single-digit contingent earn-out payments based on net sales. More details....

Stock Symbol: (NSDQ: MEIP)


Read at ChinaBio Today


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->